Zorblesia™ (SD-101)
Epidermolysis Bullosa (all subtypes)
Phase 3/Pre-NDAActive
Key Facts
Indication
Epidermolysis Bullosa (all subtypes)
Phase
Phase 3/Pre-NDA
Status
Active
Company
About Paradigm Therapeutics
Paradigm Therapeutics is a private, clinical-stage biotech company singularly focused on developing Zorblesia™ (SD-101), a breakthrough topical therapy for all subtypes of Epidermolysis Bullosa (EB). The company acquired the global rights to this late-stage asset in 2023 and is advancing it toward a planned NDA submission in the second half of 2025, supported by strategic investments from Eshelman Ventures. Paradigm operates as a lean, development-centric organization aiming to deliver the first whole-body topical treatment for this devastating rare genetic skin disorder.
View full company profile